FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2238590209> ?p ?o ?g. }

• W2238590209 endingPage "613" @default.
• W2238590209 startingPage "606" @default.
• W2238590209 abstract "Patients with inoperable non-small-cell lung cancer (NSCLC) were randomly assigned to receive one of three dosage regimens: (1) vindesine and cisplatin (VP); (2) mitomycin, vindesine, and cisplatin (MVP); or (3) etoposide and cisplatin alternating with vindesine and mitomycin (EP/VM). In 199 assessable patients, the response rates were VP, 33%; MVP, 43%; and EP/VM, 19%. The addition of mitomycin to the VP regimen did not significantly improve the response rate. The response rate was significantly lower with the EP/VM regimen than with the MVP regimen (P less than .01). The median survival times were VP, 50 weeks; MVP, 42 weeks; and EP/VM, 40 weeks. These differences were not significant. Grade III or IV thrombocytopenia was significantly greater (P less than .01) in MVP patients (22%) than in the VP (5%). Other toxicities were similar in the three groups. Analyses of prognostic factors showed that treatment with MVP, sex, and histologic classification (squamous cell carcinoma) were predictive of improved response. Important factors for improved survival, according to the Cox regression analysis, were the stage of disease, performance status, sex, weight loss before diagnosis, and hemoglobin concentration." @default.
• W2238590209 created "2016-06-24" @default.
• W2238590209 creator A5002461553 @default.
• W2238590209 creator A5003703815 @default.
• W2238590209 creator A5004024254 @default.
• W2238590209 creator A5009766343 @default.
• W2238590209 creator A5017396574 @default.
• W2238590209 creator A5023792530 @default.
• W2238590209 creator A5040839997 @default.
• W2238590209 creator A5059046154 @default.
• W2238590209 creator A5074857320 @default.
• W2238590209 creator A5084771205 @default.
• W2238590209 date "1991-04-01" @default.
• W2238590209 modified "2023-09-25" @default.
• W2238590209 title "A randomized trial in inoperable non-small-cell lung cancer: vindesine and cisplatin versus mitomycin, vindesine, and cisplatin versus etoposide and cisplatin alternating with vindesine and mitomycin." @default.
• W2238590209 cites W1670187765 @default.
• W2238590209 cites W1755983531 @default.
• W2238590209 cites W1803099259 @default.
• W2238590209 cites W1856648916 @default.
• W2238590209 cites W1865435071 @default.
• W2238590209 cites W1909306097 @default.
• W2238590209 cites W1975549289 @default.
• W2238590209 cites W1979300931 @default.
• W2238590209 cites W1991997280 @default.
• W2238590209 cites W2026613796 @default.
• W2238590209 cites W202841003 @default.
• W2238590209 cites W2031072429 @default.
• W2238590209 cites W2037243913 @default.
• W2238590209 cites W2039243236 @default.
• W2238590209 cites W2050494290 @default.
• W2238590209 cites W2059563719 @default.
• W2238590209 cites W2066638166 @default.
• W2238590209 cites W2096471429 @default.
• W2238590209 cites W2109539147 @default.
• W2238590209 cites W2143594378 @default.
• W2238590209 cites W2167805334 @default.
• W2238590209 cites W2178828310 @default.
• W2238590209 cites W2197997348 @default.
• W2238590209 cites W2201267472 @default.
• W2238590209 cites W2228760793 @default.
• W2238590209 cites W2262696150 @default.
• W2238590209 cites W2291356857 @default.
• W2238590209 cites W2402088917 @default.
• W2238590209 cites W2404805773 @default.
• W2238590209 cites W2410654427 @default.
• W2238590209 cites W2411077152 @default.
• W2238590209 cites W2413853954 @default.
• W2238590209 cites W2417349385 @default.
• W2238590209 cites W2444365962 @default.
• W2238590209 doi "https://doi.org/10.1200/jco.1991.9.4.606" @default.
• W2238590209 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/1648597" @default.
• W2238590209 hasPublicationYear "1991" @default.
• W2238590209 type Work @default.
• W2238590209 sameAs 2238590209 @default.
• W2238590209 citedByCount "67" @default.
• W2238590209 countsByYear W22385902092012 @default.
• W2238590209 countsByYear W22385902092017 @default.
• W2238590209 countsByYear W22385902092018 @default.
• W2238590209 countsByYear W22385902092019 @default.
• W2238590209 countsByYear W22385902092020 @default.
• W2238590209 countsByYear W22385902092021 @default.
• W2238590209 countsByYear W22385902092022 @default.
• W2238590209 crossrefType "journal-article" @default.
• W2238590209 hasAuthorship W2238590209A5002461553 @default.
• W2238590209 hasAuthorship W2238590209A5003703815 @default.
• W2238590209 hasAuthorship W2238590209A5004024254 @default.
• W2238590209 hasAuthorship W2238590209A5009766343 @default.
• W2238590209 hasAuthorship W2238590209A5017396574 @default.
• W2238590209 hasAuthorship W2238590209A5023792530 @default.
• W2238590209 hasAuthorship W2238590209A5040839997 @default.
• W2238590209 hasAuthorship W2238590209A5059046154 @default.
• W2238590209 hasAuthorship W2238590209A5074857320 @default.
• W2238590209 hasAuthorship W2238590209A5084771205 @default.
• W2238590209 hasConcept C126322002 @default.
• W2238590209 hasConcept C126894567 @default.
• W2238590209 hasConcept C141071460 @default.
• W2238590209 hasConcept C143998085 @default.
• W2238590209 hasConcept C2776256026 @default.
• W2238590209 hasConcept C2776694085 @default.
• W2238590209 hasConcept C2776755627 @default.
• W2238590209 hasConcept C2778119113 @default.
• W2238590209 hasConcept C2778239845 @default.
• W2238590209 hasConcept C2779321808 @default.
• W2238590209 hasConcept C2779338040 @default.
• W2238590209 hasConcept C2779429289 @default.
• W2238590209 hasConcept C2781413609 @default.
• W2238590209 hasConcept C71924100 @default.
• W2238590209 hasConcept C90924648 @default.
• W2238590209 hasConceptScore W2238590209C126322002 @default.
• W2238590209 hasConceptScore W2238590209C126894567 @default.
• W2238590209 hasConceptScore W2238590209C141071460 @default.
• W2238590209 hasConceptScore W2238590209C143998085 @default.
• W2238590209 hasConceptScore W2238590209C2776256026 @default.
• W2238590209 hasConceptScore W2238590209C2776694085 @default.
• W2238590209 hasConceptScore W2238590209C2776755627 @default.
• W2238590209 hasConceptScore W2238590209C2778119113 @default.
• W2238590209 hasConceptScore W2238590209C2778239845 @default.
• W2238590209 hasConceptScore W2238590209C2779321808 @default.

• next